Company Filing History:
Years Active: 2000
Title: Jerry Griffin - Innovator in Cardiac Implant Technology
Introduction
Jerry Griffin, a pioneering inventor based in Chicago, IL, has made significant strides in the field of cardiac technology. With a focus on innovations that enhance heart health, Griffin holds one patent that reflects his dedication to improving medical outcomes for patients with coronary issues.
Latest Patents
Griffin's patent is for a "Transmyocardial Implant with Coronary Stent." This invention features a hollow rigid conduit composed of two portions. The first portion is designed to be larger than the initial lumen diameter of a coronary vessel while remaining smaller than the enlarged lumen diameter. The second portion extends through the myocardium into a heart chamber. This innovative implant integrates a stent, which can transition from a first, smaller diameter suitable for insertion to a second, enlarged diameter that dilates the lumen to the required size. This clever design allows for improved placement and function within the cardiovascular system, showcasing Griffin’s expertise in addressing complex medical challenges.
Career Highlights
Jerry Griffin works at Heartstent Corporation, an organization dedicated to advancing cardiovascular technologies. His contributions here signify his commitment to research and development in the medical device industry. Griffin's innovative insights help drive the company's mission to provide effective solutions for heart patients.
Collaborations
Throughout his career, Griffin has worked with esteemed colleagues such as Robert A. Eno and Donald C. Harrison. Collaborating with these professionals has allowed Griffin to leverage combined knowledge and expertise, fostering an environment of innovation within the company.
Conclusion
Jerry Griffin’s contributions to cardiac implant technology reflect a profound understanding of medical needs and engineering solutions. Through his innovative transmyocardial implant, he exemplifies how dedicated inventors can transform patient care in significant ways. As he continues his work at Heartstent Corporation, Griffin remains focused on enhancing the quality of life for those affected by coronary issues.